Home > Colorectal Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.
Note: Separate PDQ summaries on Colorectal Cancer Prevention; Colon Cancer Treatment; and Rectal Cancer Treatment are also available.
Evidence of Benefit Associated With Colorectal Cancer Screening
Based on solid evidence, screening for colorectal cancer (CRC) reduces CRC mortality, but there is little evidence that it reduces all-cause mortality, possibly because of an observed increase in other causes of death.
Incidence and mortality
Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide  and the second leading cause of cancer deaths in the United States. It is estimated that there will be 135,430 new cases diagnosed in the United States in 2017 and 50,260 deaths due to this disease. From 2004 to 2013, CRC incidence declined by 3% per year among adults aged 50 years and older. However, in adults younger than 50 years, CRC incidence rates have been increasing by about 2% per year. From 2005 to 2014, mortality from CRC declined by 2.5% per year. Incidence is higher in men than in women. The incidence rates range from 43.3 per 100,000 per year in Hispanic men to 61.2 per 100,000 per year in African American men. In women, the incidence rates range from 30.0 per 100,000 per year in Hispanics to 46.0 per 100,000 per year in African Americans. The age-adjusted mortality rates are 18.6 per 100,000 per year in men and 13.1 per 100,000 per year in women. About 4.5% of Americans are expected to develop the disease within their lifetime, and the lifetime risk of dying from CRC is 1.9%.[3,4] Age-specific incidence and mortality rates show that most cases are diagnosed after age 50 years; about 4% of CRC cases occur in patients younger than age 50 years.[5,6]
Long-term trends in CRC were addressed in an analysis of national data for the period 1975 to 2010. Incidence increased for men from 1975 to 1985, but there were marked declines from 1985 to 1995 for both men and women followed by a nonsignificant increase from 1995 to 1998, then marked declines from 1998 to 2010. Death rates from CRC have declined since 1984 in both men and women, with an accelerated rate of decline since 2002 for men and since 2001 for women. From 1997 to 2010, CRC incidence declined for all racial/ethnic groups. The fastest annual rate of decline occurred in men and women aged 65 years or older, but short-term incidence trends increased annually for individuals younger than 50 years in most population subgroups. Incidence rates of distal colon and rectal cancers decreased in men and women for all ages combined. Incidence rates of proximal colon cancer also decreased in men and women for all race/ethnicities combined.
The major factor that increases a person's risk for CRC is increasing age. Risk increases dramatically after age 50 years with 90% of all CRCs diagnosed after this age. History of CRC in a first-degree relative, especially occurring before age 55, roughly doubles the risk. While a personal history of CRC or high-risk adenomas (i.e., large [>1cm] tubular adenomas, sessile serrated adenomas, or multiple adenomas) indicates increased future risk of cancer, follow-up of these individuals after they have undergone screening is considered "surveillance," and not screening.
Genetic, experimental, and epidemiologic  studies suggest that CRC results from complex interactions between inherited susceptibility and environmental or lifestyle factors. Efforts to identify causes led to the hypothesis that adenomatous polyps (adenomas) are precursors of most CRCs. In effect, measures that reduce the incidence and prevalence of adenomas may result in a subsequent decrease in the risk of CRCs; however, some CRC mortality may be caused by fast-growing lesions or lesions that do not pass through an adenomatous phase. Overall, details about the growth rates of adenomas and CRC are unknown; most likely, there is a broad spectrum of growth patterns, including formation and spontaneous regression of adenomas.[13,14]
Fecal Occult Blood Test (FOBT)
In FOBT testing, stool samples are collected and analyzed for the presence of small amounts of blood. The first generation of FOBTs used guaiac-based assays to detect blood, which are less sensitive and less specific than immunochemical-based testing. The now-classic randomized controlled trials (RCTs) that assessed colorectal cancer (CRC) mortality reduction all used guaiac-based testing. The finding of decreased CRC mortality provided a major foundation for recommendations to do CRC screening. The first-generation guaiac-based tests are being replaced by more sensitive and more specific immunochemical tests that have not been-and likely will never be-assessed in RCTs in a no-screening control group.
In this setting, the RCT evidence about guaiac-based testing is reviewed briefly here, with further discussion of how immunochemical FOBT (iFOBT or FIT) may provide improved sensitivity and specificity. Generally, if guaiac FOBT (gFOBT) is acceptable as a screening test (as shown in RCTs), then a strong case can be made for using a more sensitive and more specific test like FIT.
gFOBT collection details vary somewhat for different tests, but they typically involve collection of as many as three different specimens on 3 different days, with small amounts from one specimen smeared by a wooden stick on a card with two windows or otherwise placed in a specimen container.
The guaiac test identifies peroxidase-like activity that is characteristic of human and nonhuman hemoglobin. Thus, the test records blood from ingested meat, upper airway bleeding such as epistaxis, upper gastrointestinal (GI) bleeding, and colonic lesions.
A systematic review regarding evidence of benefit was conducted through the Cochrane Collaboration. It examined all CRC screening randomized trials that involved gFOBT testing done on more than one occasion. The combined results showed that trial participants allocated to screening had a 16% lower CRC mortality (relative risk [RR], 0.84; 95% confidence interval [CI], 0.78-0.90). There was no difference in all-cause mortality between the screened groups and the control groups (RR, 1.00; 95% CI, 0.99-1.02). The trials reported a low positive predictive value (PPV) for the FOBT test, suggesting that most positive tests were false positives. The PPV was 5.0% to 18.7% in the trials using nonrehydrated slides (Funen and Nottingham), and it was 0.9% to 6.1% in the trials using rehydrated slides (Goteborg and Minnesota). The report contained no discussion about contamination in the control arms of the trials and no information about treatment by disease stage.[1,2]
On initial (prevalence) examinations, 1% to 5% of unselected persons tested with gFOBT have positive test results. Of those who tested positive, approximately 2% to 10% have cancer and approximately 20% to 30% have adenomas,[3,4] depending on how the test was done. Data from RCTs of gFOBT testing are summarized in Table 3.
Four controlled clinical trials have been completed or are in progress to evaluate the efficacy of screening utilizing gFOBT. While more-sensitive stool blood tests based on measuring human hemoglobin have been developed (and are discussed later), results about their performance in RCTs have not been yet reported. For gFOBT, the Swedish trial was a targeted study for individuals aged 60 to 64 years. The English trial selected candidates from lists of family practitioners. The Danish trial offered screening to a population aged 45 to 75 years who were randomly assigned to a control or study group.[7,8]
The Minnesota trial randomly assigned 46,551 men and women aged 50 to 80 years to one of three arms: colorectal cancer screening with gFOBT, rehydrated FOBT every year (15,570), every 2 years (15,587), or control (15,394). This trial demonstrated that annual FOBT screening decreased mortality from CRC by 33% after 18 years of follow-up (RR, 0.67; 95% CI, 0.51-0.83, compared with the control group) and that biennial testing resulted in a 21% relative mortality reduction (RR, 0.79; 95% CI, 0.62-0.97). Some part of the reduction may have been attributed to chance detection of cancer by colonoscopies; rehydration of guaiac test slides greatly increased positivity and consequently increased the number of colonoscopies performed. Subsequent analyses by the Minnesota investigators using mathematical modeling suggested that for 75% to 84% of the patients, mortality reduction was achieved because of sensitive detection of CRCs by the test; chance detection played a modest role (16%-25% of the reduction). Nearly 85% of patients with a positive test underwent diagnostic procedures that included colonoscopy or double-contrast barium enema plus flexible sigmoidoscopy (FS). After 18 years of follow-up, the incidence of CRC was reduced by 20% in the annually screened arm and 17% in the biennially screened arm. With follow-up through 30 years, there was a sustained reduction in CRC mortality of 32% in the annually screened arm (RR, 0.68; 95% CI, 0.56-0.82) and 22% in the biennially screened arm (RR, 0.78; 95% CI, 0.65-0.93). There was no reduction in all-cause mortality in either screened arm (RR, 1.00; 95% CI, 0.99-1.01 for the annually screened arm; and RR, 0.99; 95% CI, 0.98-1.01 for the biennially screened arm). Important information that was not reported includes the treatment of CRC cases by stage by arm and the extent of CRC screening in each arm by FOBT, sigmoidoscopy, or colonoscopy after the completion of the trial protocol.[12,13]
The English trial allocated approximately 76,000 individuals to each arm. Those in the screened arm were offered nonrehydrated gFOBT testing every 2 years for three to six rounds from 1985 to 1995. At a median follow-up of 7.8 years, 60% completed at least one test, and 38% completed all tests. Cumulative incidence of CRC was similar in both arms, and the trial reported a RR reduction of 15% in CRC mortality (odds ratio [OR], 0.85; 95% CI, 0.74-0.98). The serious complication rate of colonoscopy was 0.5%. There were five deaths within 30 days of surgery for screen-detected CRC or adenoma in a total of 75,253 individuals screened. After a median follow-up of 11.8 years, no difference in CRC incidence between the intervention and control groups was observed. The disease-specific mortality rate ratio associated with screening was 0.87 (0.78-0.97; P = .01). The rate ratio for death from all causes was 1.00 (0.98-1.02; P = .79). When the median follow-up was extended to 19.5 years, there was a 9% reduction in CRC mortality (RR, 0.91; 95% CI, 0.84-0.98) but no reduction in CRC incidence (RR, 0.97; 95% CI, 0.91-1.03), or death from all causes (RR, 1.00; 95% CI, 0.99-1.02).
The Danish trial in Funen, Denmark, entered approximately 31,000 individuals into two arms, in which individuals in the screened arm were offered nonrehydrated gFOBT testing every 2 years for nine rounds over a 17-year period. Sixty-seven percent completed the first screen, and more than 90% of individuals invited to each subsequent screen underwent FOBT testing. This trial demonstrated an 18% reduction in CRC mortality at 10 years of follow-up, 15% at 13 years of follow-up (RR, 0.85; 95% CI, 0.73-1.00), and 11% at 17 years of follow-up (RR, 0.89; 95% CI, 0.78-1.01). CRC incidence and overall mortality were virtually identical in both arms.
The Swedish trial in Goteborg enrolled all of its 68,308 citizens in the city who were born between 1918 and 1931 and were aged 60 to 64 years, and randomly assigned them to screening and control groups of nearly equal size. Participants in the control group were not contacted and were unaware they were part of the trial. Screening was offered at different frequencies to three different cohorts according to year of birth. Screening was done using the gFOBT Hemoccult-II test after dietary restriction. Nearly 92% of tests were rehydrated. Individuals with a positive test result were invited to an examination consisting of a case history, FS, and double-contrast barium enema. Follow-up ranged from 6 years 7 months to 19 years 5 months, depending on the date of enrollment. The primary endpoint was CRC-specific mortality. The overall screening compliance rate was 70%, and 47.2% of participants completed all screenings. Of the 2,180 participants with a positive test, 1,890 (86.7%) underwent a complete diagnostic evaluation with 104 cancers and 305 adenomas of at least 10 mm detected. In total, there were 721 CRCs (152 Dukes D, 184 Dukes C) in the screening group and 754 CRCs (161 Dukes D, 221 Dukes C) in the control group, with an incidence ratio of 0.96 (95% CI, 0.86-1.06). Deaths from CRC were 252 in the screening group and 300 in the control group, with a mortality ratio of 0.84 (95% CI, 0.71-0.99). This CRC mortality difference emerged after 9 years of follow-up. Deaths from all causes were very similar in the two groups, with a mortality ratio of 1.02 (95% CI, 0.99-1.06).
All trials have shown a more favorable stage distribution in the screened population than in controls (refer to Table 3). Data from the Danish trial indicated that while the cumulative incidence of CRC was similar in the screened and control groups, a higher percentage of CRCs and adenomas were Dukes A and Dukes B lesions in the screened group. A meta-analysis of all previously reported randomized trials using biennial FOBT showed no overall mortality reduction by gFOBT screening (RR, 1.002; 95% CI, 0.989-1.085). The RR of CRC death in the gFOBT arm was 0.87 (95% CI, 0.8-0.95), and the RR of non-CRC death in the gFOBT group was 1.02 (95% CI, 1.00-1.04; P = .015).
Mathematical models have been constructed to extrapolate the results of screening trials and screening programs for benefit of the general population in community health care delivery settings. These models project that using currently available screening methodology can reduce CRC mortality or increase life expectancy.
Immunochemical FOBTs (iFOBT or FIT): Nonrandomized Controlled Trial Evidence to Assess Lesion Detection
The immunochemical FOBT (iFOBT or FIT) was developed to detect intact human hemoglobin. The advantage of FIT over gFOBT is that it does not detect hemoglobin from nonhuman dietary sources. Also, FIT does not detect partly digested human hemoglobin that comes from the upper respiratory or GI tract. Preliminary studies of several commercially developed FIT tests define their sensitivity and specificity compared with concurrently performed colonoscopy. The studies also examine these outcomes for different cutpoints, and the benefit of multiple versus single stool samples.[25,26]
Overall, FIT testing is much more sensitive than gFOBT, and it is more sensitive for cancers than for benign neoplasias. As expected, higher cutpoints decrease sensitivity and increase specificity.
A meta-analysis of FIT testing  assessed the diagnostic accuracy of FITs in asymptomatic average-risk adults. The pooled sensitivity and specificity were 0.71 (95% CI, 0.58-0.81) and 0.94 (95% CI, 0.91-0.96) from studies using colonoscopy in persons with negative and positive FITs. Because FITs are quantitative, selection of different cut-off values results in different sensitivities and specificities, with sensitivities reaching 96% or 100% and specificities declining to about 88%, in small studies. Variations in sample preparation and in numbers of samples analyzed (one, two, or three) suggest that this is a developing field. Overall, FIT provides a substantially improved sensitivity compared with gFOBT, although with some compromise in specificity.
In one study, 2,188 patients scheduled for colonoscopy because of an elevated risk due to personal or family history of colorectal neoplasm, positive FIT result, change in bowel habits, anemia, abdominal pain with weight loss, or anal symptoms were invited to participate in a comparative assessment of FIT against colonoscopy findings. After exclusions for health and cognitive reasons, 1,859 patients were offered FIT, 1,116 patients adhered to the protocol, and 1,000 patients completed the procedure. Sensitivity and specificity were calculated at various cutpoints. At a cutpoint of 100 ng/mL, sensitivity and specificity were, respectively, 88.2% and 89.7% for cancer and 61.5% and 91.4% for any clinically significant neoplasia (cancer and advanced polyps). At 150 ng/mL the respective sensitivities and specificities were 82.4% and 91.9% for cancer and 53.8% and 95% for any clinically significant neoplasia. Calculations were based on the most severe pathologic finding from colonoscopy and the highest fecal-hemoglobin concentration measured by FIT applied to three stool samples collected before the colonoscopy. Stool samples were collected by patients following FIT kit instructions and analyzed by the OC-MICRO analyzer (from the Eiken Chemical Company in Tokyo, Japan).
In another study, 21,805 asymptomatic patients received FIT based on one stool sample collected by patients following the kit instructions on the day of or the day before the colonoscopy. Stool samples were analyzed using the Magstream 1,000/Hem SP automated system (from Fujirebio Incorporated, Tokyo, Japan), which is based on the HemeSelect system (from Beckman Coulter, Palo Alto, California). Sensitivity and specificity based on subsequent colonoscopy were, respectively, 65.8% and 94.6% for cancer and 27.1% and 95.1% for advanced neoplasm.
Fecal immunochemical tests may vary with regard to numbers of stools tested and cut-off values for a positive result.
The performance and acceptability of FIT over time was assessed by Kaiser-Permanente of Northern and Southern California in a screening program. A retrospective cohort of 323,349 persons aged 50 to 70 years was followed for up to four screening rounds over 4 years. Of patients invited, participation in round one was 48.2%, and of those remaining eligible, 75.3% to 86.1% participated in subsequent rounds. The authors reported that "programmatic FIT screening detected 80.4% of patients with CRC diagnosed within 1 year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds." An important observation was the degree of participation found. One limitation of the study is that it was not clear how work-up bias was addressed; e.g., when individuals with a positive test result are preferentially worked up to ascertain the presence or absence of CRC, while individuals with a negative test, but who might have CRC, are not. Although a "look-back" method was used to ascertain whether an individual had cancer, it is not clear that the duration of follow-up was long enough to discover everyone who should have been included in the denominator of the sensitivity calculation. Nevertheless, the results suggest that subsequent FIT results were at least partially independent of previous results. Longer follow-up may help clarify this issue. Mortality reduction could not be assessed in this study.
A systematic review to evaluate the comparative diagnostic performance of gFOBT and FIT in the context of a decision to introduce screening for CRC in the United Kingdom, included 33 studies evaluating gFOBT and 35 studies evaluating FIT, including nine that evaluated both gFOBT and FIT. There was no clear evidence for superiority of either gFOBT or FIT. Sensitivities for the detection of all neoplasms ranged from 6.2% (specificity 98%) to 83.3% (specificity 98.4%) for gFOBTs and 5.4% (specificity 98.5%) to 62.6% (specificity 94.3%) for FIT. Increasing sensitivity entailed adjusting cut-points to decrease specificity. Sensitivities were higher for the detection of CRC and lower for adenomas.
Some studies have utilized the quantitative ability of FIT to consider detection and specificity at various cutpoints for defining a positive test. One study  found that reducing the cutpoint from the standard 100 ng/mL to 50 ng/mL increased the detection of advanced adenomas but had little impact on the detection of cancer. The number of colonoscopies required to detect a single advanced adenoma or cancer increased from 1.9 to 2.3; a 20% increase. Specificity declined from 97.8% to 96%.
Potential false-positive test results due to an increased risk of upper GI bleeding are of concern with FOBT testing and pretest protocols, therefore; low-dose aspirin regimens are discontinued for a week or more before FOBT. The performance of FIT was tested in an ongoing diagnostic study (2005-2009) at 20 internal medicine GI practices in southern Germany. Nineteen hundred seventy-nine patients (233 regular low-dose aspirin users and 1,746 never users) were identified in the records for inclusion in the analysis. All patients provided one stool sample taken within a week before colonoscopy preparation, which was collected according to instructions in a container that was kept refrigerated or frozen until rendered to the clinic on the day of colonoscopy, and the patients agreed to complete a standard questionnaire regarding the use of analgesics and low-dose aspirin (for prevention of cardiovascular disease). Stool samples were thawed within a median of 4 days after arrival at the central laboratory (shipped frozen from the recipient clinics). Fecal occult blood levels were measured by two automated FIT tests according to the manufacturer's instructions (RIDASCREEN Haemoglobin and RIDASCREEN Haemo-/Haptoglobin Complex, r-biopharm, Bensheim, Germany) following clinical procedures and blinded to colonoscopy results. Advanced neoplasms were found in 24 aspirin users (10.3%) and in 181 nonusers (10.4%). At the cutpoint recommended by the manufacturer, sensitivities for the two tests were 70.8% (95% CI, 48.9%-87.4%) for users compared with 35.9% (95% CI, 28.9%-43.4%) for nonusers and 58.3% (95% CI, 36.6%-77.9%) for users compared with 32% (95% CI, 25.3%-39.4%) for nonusers (P = .001 and P = .01, respectively). Specificities were 85.7% (95% CI, 80.2-90.1%) for users compared with 89.2% (95% CI, 87.6%-90.7%) for nonusers and 85.7% (95% CI, 80.2%-90.1%) for users compared with 91.1% (95% CI, 89.5%-92.4%) for nonusers (P = .13 and P = .01, respectively). For these FITs, sensitivity for advanced neoplasms was notably higher with the use of low-dose aspirin while specificity was only slightly reduced, suggesting that there might be an advantage to aspirin use to increase sensitivity without much decrease in specificity.
The flexible fiberoptic sigmoidoscope was introduced in 1969. The 60 cm flexible sigmoidoscope became available in 1976. The flexible sigmoidoscope permits a more complete examination of the distal colon with more acceptable patient tolerance than the older rigid sigmoidoscope. The rigid instrument can discover 25% of polyps, and the 60 cm scope can find as many as 65% of them. The finding of an adenoma by FS may warrant a colonoscopy to evaluate the more proximal portion of the colon.[35,36] The prevalence of advanced proximal neoplasia is increased in patients with a villous or tubulovillous adenoma distally and is also increased in those aged 65 years or older with a positive family history of CRC and with multiple distal adenomas. Most of these adenomas are polypoid, flat, and depressed lesions, which may be somewhat more prevalent than previously recognized.
Five sigmoidoscopy screening RCTs have reported incidence and mortality results. These are the Norwegian Colorectal Cancer Prevention (NORCCAP) trial; the Telemark trial in Norway; the United Kingdom trial; the SCORE trial in Italy; and the U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Participants were aged 50 to 59 years in the Telemark trial, aged 55 to 74 years in PLCO, and aged 55 to 64 years in the other three trials. Together the trials enrolled 166,000 participants in the screened groups and 250,000 participants in the control groups. Follow-up ranged from 6 to 13 years. Results were summarized in three systematic reviews. There was an 18% relative reduction in CRC incidence (RR, 0.82; 95% CI, 0.75-0.89), an overall 28% relative reduction in CRC mortality (RR, 0.72; 95% CI, 0.65-0.80), a 31% relative reduction in the incidence of left-sided CRC (RR, 0.69; 95% CI, 0.63-0.74), and a 46% relative reduction in the mortality of left-sided CRC (RR, 0.54; 95% CI, 0.43-0.67). There was no effect on all-cause mortality.[39,40] Findings from the NORCCAP trial with follow-up through 11 years are very similar to these results.
There are no strong direct data to determine frequency of screening tests in programs of screening.
Combination of FOBT and Flexible Sigmoidoscopy
A combination of FOBT and sigmoidoscopy might increase the detection of lesions in the left colon (compared with sigmoidoscopy alone) while also increasing the detection of lesions in the right colon. Sigmoidoscopy detects lesions in the left colon directly but detects lesions in the right colon only indirectly when a positive sigmoidoscopy (that may variously be defined as a finding of advanced adenoma, any adenoma, or any polyp) is used to trigger a colonoscopic examination of the whole colon.
In 2,885 veterans (97% male; mean age 63 years), the prevalence of advanced adenoma at colonoscopy was 10.6%. The estimate was that combined screening with one-time FOBT and sigmoidoscopy would detect 75.8% (95% CI, 71.0%-80.6%) of advanced neoplasms. Examination of the rectum and sigmoid colon during colonoscopy was defined as a surrogate for sigmoidoscopy. This represented a small but statistically insignificant increase in the rate of detection of advanced neoplasia when compared with FS alone (70.3%; 95% CI, 65.2%-75.4%). The latter result could be achieved assuming that all patients with an adenoma in the distal colon undergo complete colonoscopy. Advanced neoplasia was defined as a lesion measuring at least 10 mm in diameter, containing 25% or more villous histology, high-grade dysplasia, or invasive cancer. One-time use of FOBT differs from the annual or biennial application reported in those studies summarized in Table 3.
A study of 21,794 asymptomatic persons (72% were men), who had both colonoscopy and FIT for occult blood, compared the detection of right-sided cancers as triggered by different test results. FIT alone resulted in a sensitivity of 58.3% and a specificity of 94.5% for proximal cancer diagnosis. FIT plus the finding of advanced neoplasia in the rectosigmoid colon yielded a sensitivity of 62.5% and a specificity of 93%. In this study, the addition of sigmoidoscopy to FIT did not substantially improve the detection of right-sided colon cancers, compared with FIT alone.
The NORCCAP screening trial randomly assigned 20,780 men and women, aged 50 to 64 years, living in Oslo city or Telemark county, Norway, to a once-only, FS-only group (10,392) or a once-only, combination of FS and FOBT with FlexSure OBT group (10,388). The 79,430 remaining individuals in those areas were assigned as controls. After 11 years of follow up, there was a 20% reduction in CRC incidence (RR, 0.80; 95% CI, 0.70-0.92) and a 27% reduction in CRC mortality (RR, 0.73; 95% CI, 0.56-0.94), with no difference in all-cause mortality (RR, 0.97; 95% CI, 0.93-1.02). The results in the two screening subgroups were not statistically different. The RRs for CRC incidence, compared with the controls, were 0.72 for the FS group and 0.88 for the FS with FOBT group, with overlapping CIs (P = .11 for heterogeneity). The corresponding RRs for CRC mortality were 0.84 and 0.62, with overlapping CIs (P = .20 for heterogeneity). The screening findings were very similar in these two subgroups with 17% adenomas, 4.5% advanced adenomas, and 20 versus 21 CRCs. About 20% of men and women in the two screening subgroups were referred for colonoscopy, and 95% of the referred attended colonoscopy.
Because there are no completed RCTs of colonoscopy, evidence of benefit is indirect. Most indirect evidence is about detection rate of lesions that may be clinically important (like early CRC or advanced adenomas). Some case-control results are available. Three RCTs (NCT01239082, NCT00883792, and NCT00906997) of colonoscopy have been initiated.
The Nordic-European Initiative on Colorectal Cancer (NordICC) is a population-based randomized trial to investigate the effectiveness of colonoscopy screening on CRC incidence and mortality in several European countries (Norway, Poland, Sweden, and the Netherlands). NordICC comprises 94,959 men and women aged 55 to 64 years who were randomly selected from population registers and randomly assigned in a 1:2 ratio to one time colonoscopy screening or no screening. Control participants were not contacted. The primary endpoint is a comparison of the 15-year CRC mortality rates. Participation rates, participant experience, lesion yield, and complications of colonoscopy screening in the participating countries have been reported.
Among 31,420 eligible participants randomly assigned to colonoscopy, 12,574 (40.0%) underwent screening. Participation rates were 60.7% in Norway (5354 of 8,816), 39.8% in Sweden (486 of 1,222), 33.0% in Poland (6,004 of 18,188), and 22.9% in the Netherlands (730 of 3,194). The cecum intubation rate of 97.2% was very similar across countries, with 9,726 participants (77.4%) not receiving sedation-10.8% in Norway rising to 90% in the Netherlands. Among the 12,574 screenees, there was one perforation (0.01%), two postpolypectomy serosal burns (0.02%), and 18 cases of bleeding caused by polypectomy (0.14%). Sixty-two individuals (0.5%) were diagnosed with CRC (50 distal and 14 proximal) and 3,861 (30.7%) had adenomas. There were 725 (5.8%) distal versus 562 (4.5%) high-risk adenomas, and 2,439 (19.4%) distal versus 1,078 (8.6%) proximal serrated polyps. Performance differed significantly among endoscopists; recommended benchmarks for cecal intubation (95%) were not met by 17.1% of endoscopists and benchmarks for adenoma detection (25%) were not met by 28.6% of endoscopists. Moderate or severe abdominal pain after colonoscopy was reported by 16.7% of participants examined with standard air insufflation versus 4.2% examined with carbon dioxide (CO2) insufflation.
Prevalence of lesions in asymptomatic populations
In a colonoscopy study of 3,121 predominantly male U.S. veterans (mean age, 63 years), advanced neoplasia (defined as an adenoma that was ≥10.0 mm in diameter, a villous adenoma, an adenoma with high-grade dysplasia, or invasive cancer) was identified in 10.5% of the individuals. Among patients with no adenomas distal to the splenic flexure, 2.7% had advanced proximal neoplasia. Patients with large adenomas (≥10.0 mm) or small adenomas (<10.0 mm) in the distal colon were more likely to have advanced proximal neoplasia (OR, 3.4; 90% CI, 1.8-6.5) than were patients with no distal adenomas (OR, 2.6; 90% CI, 1.7-4.1). One-half of those with advanced proximal neoplasia had no distal adenomas. In a study of 1,994 adults (aged 50 years or older) who underwent colonoscopy screening (as part of a program sponsored by an employer), 5.6% had advanced neoplasms. Forty-six percent of those with advanced proximal neoplasms had no distal polyps (hyperplastic or adenomatous). If colonoscopy screening is performed only in patients with distal polyps, about half the cases of advanced proximal neoplasia will not be detected.
A study of colonoscopy in women compared the yield of sigmoidoscopy versus colonoscopy. Of the 1,463 women, cancer was found in one woman and advanced colonic neoplasia was found in 72 women (4.9%), which is about 50% of the prevalence in men. The authors focused, however, on RR (i.e., RR of missing an advanced neoplasm) as the outcome, instead of absolute risk of such neoplasms, which is substantially lower in women. In addition, the natural history of advanced neoplasia is not known, so its importance as an outcome in studies of detection is not clear.
Analysis of data from a colonoscopy-based screening program in Warsaw, Poland demonstrated higher rates of advanced neoplasia in men than in women. Of the 43,042 participants aged 50 to 66 years, advanced neoplasia was detected in 5.9% (5.7% in women with a family history of CRC, 4.3% in women without a family history of CRC, 12.2% in men with a family history of CRC, and 8.0% in men without a family history of CRC). Clinically significant complications requiring medical intervention were rare (0.1%), consisting of five perforations, 13 episodes of bleeding, 22 cardiovascular events, and 11 other events over the entire population of 50,148 screened persons. There were no deaths. The author also reported that collection of 30-day complications data was not systematic; therefore, the data may not be reliable.
Detection of right-sided versus left-sided lesions
Flat or difficult-to-detect lesions include serrated polyps, which may be more common in the right colon than in the left. The term serrated polyp is currently used to include hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed serrated polyps.[49,50] The clinical significance of these lesions is uncertain because the natural history of any polypoid lesion is difficult to learn. However, the histologic and molecular characteristics of some serrated lesions suggest possibly important malignant potential (e.g., mutations in the BRAF gene may be an early step toward carcinogenesis in serrated polyps). This potential, along with the challenges of detecting flat lesions, may partially account for recent reports of a colonoscopy's lesser protective effect in the right colon compared to the left colon.
In 2011, authors of one study reported variability of detection rates for proximal serrated polyps. They studied 15 colonoscopists on faculty at one university and showed, during the years 2000 to 2009 and observed a wide variation in detection rates for proximal serrated polyps, ranging (per colonoscopy) from 0.01 to 0.26, suggesting that many proximal serrated lesions may be missed on routine exam. The overall proportion of polyps that are "serrated" is unknown, in part because these lesions have been unappreciated and/or difficult to identify.
Adenoma detection rate (ADR)
Detection rates in colonoscopy screening vary with the rate at which the endoscopist examines the colon while withdrawing the scope. In one study, there were differences among gastroenterologists in the rates of detection of adenomas (range of the mean number of lesions per patient screened, 0.10-1.05; range of the percentage of patients with adenomas, 9.4%-23.7%) and the times of withdrawal of the scope (3.1-16.8 minutes for procedures not including polyp removal). Examiners whose mean withdrawal time was 6 minutes or more had higher detection rates than those with mean withdrawal times of less than 6 minutes (28.3% vs. 11.8%; P < .001 for any neoplasia and 6.4% vs. 2.6%; P < .005 for advanced neoplasia).
In the first 10 years of the German CRC screening program, detection of nonadvanced adenomas increased in men from 13.3% to 22.3% and in women from 8.4% to 14.9%. The great majority of the nonadvanced adenomas, however, were small (<0.5 cm) and had uncertain clinical significance. The detection of advanced adenomas and CRC increased by a much smaller amount.
Overall detection rate of adenomas and cancer may be affected by how thoroughly endoscopists search for flat adenomas and flat cancer. While the phenomenon of flat neoplasms has been appreciated for years in Japan, it has more recently been described in the United States. In a study in which endoscopists used high-resolution white-light endoscopes, flat or nonpolypoid lesions were found to account for only 11% of all superficial colon lesions, but these flat or nonpolypoid lesions were about 9.8 times as likely as polypoid lesions to contain cancer (in situ neoplasia or invasive cancer). However, because the definition of "flat or nonpolypoid" was height less than one-half of the diameter, it is likely that many lesions classified as nonpolypoid in this study would be routinely found and described by U.S. endoscopists as "sessile." The existence of very flat or depressed lesions-depressed lesions are very uncommon but are highly likely to contain cancer-requires that endoscopists pay increasing attention to this problem. Flat lesions may play a role in the phenomenon of missed cancers.
The impact of ADRs was assessed by a health maintenance organization in follow-up after 314,872 colonoscopies done from 1998 to 2010 by 136 gastroenterologists, each of whom had done at least 300 colonoscopies during that period. The goal was to determine rates of interval CRC, interval advanced CRC, and CRC death, and to relate those rates to a gastroenterologist's ADR. There were 712 interval cancers (155 advanced) and 147 CRC deaths. The risk of interval cancer from lowest-to-highest quintile of ADR was 9.8, 8.6, 8.0, 7.0, and 4.8 per 10,000 person-years of follow-up. The adjusted hazard ratio, for physicians in the highest quintile compared with the lowest, was 0.52 for any interval CRC, 0.43 for advanced CRC, and 0.38 for fatal CRC. Each 1.0% increase in ADR was associated with a 3% decrease in risk of cancer, although the CI for each quintile was broad. Limitations of the study include the inability to determine which specific feature of ADR led to reduced interval cancer; for example, it is unclear whether it was due to the following:
Another limitation is that the harms of a colonoscopy associated with ADR could not be measured.
Nonrandomized controlled trial evidence about colorectal cancer incidence or mortality reduction
Although there is no randomized controlled trial (RCT) to assess reduction of CRC incidence or mortality by colonoscopy, some case-control evidence is available. Based on case-control data about sigmoidoscopy, noted above, it has been speculated in the past that protection for the right colon might be similar to that found for the left colon. A 2009 case-control study of colonoscopy raised questions about whether the impact of colonoscopy on right-sided lesions might be different than the impact on left-sided lesions. Using a province-wide administrative database in Ontario, Canada, investigators compared cases of persons who had received a diagnosis of CRC from 1996 to 2001 and had died by 2003. Controls were selected from persons who did not die of CRC. Billing claims were used to assess exposure to previous colonoscopy. The OR for the association between complete colonoscopy and left-sided lesions was 0.33, suggesting a substantial mortality reduction. For right-sided lesions, however, the OR of 0.99 indicated virtually no mortality reduction. However, this study had limited data about whether examinations were complete to the cecum and about bowel prep. Further, many endoscopists were nongastroenterologists.
A case-control study assessed CRC reduction (not CRC mortality reduction) in the right side versus the left side. In a population-based study from Germany, data were obtained from administrative records and medical records; 1,688 case patients (with CRC) were compared with 1,932 participants (without CRC), aged 50 years or older. Data were collected about demographics, risk factors, and previous screening examinations. According to colonoscopy records, the cecum was reached 91% of the time. Colonoscopy in the previous 10 years was associated with an OR for any CRC of 0.23, for right-sided CRC of 0.44, and for left-sided CRC of 0.16. While this study does not assess CRC mortality, the results suggest that the magnitude of the right-side versus the left-side difference may be smaller than previously found. It would be extremely useful to assess right side-versus left side differences in a RCT.
Other case-control data suggest a reduction of CRC incidence on the right-side of about 64% compared with about 74% on the left-side.
Because there is no RCT evidence and case-control evidence is limited, it is important to consider the degree of mortality reduction from colonoscopy. While a figure of 90% is sometimes cited as the degree of mortality reduction, the question will not be properly answered until the European RCT that has a control group of "routine care" that involves minimal screening of any kind is completed. Until there are more reliable results from colonoscopy RCTs, studies of FS may provide the best estimate of CRC mortality incidence reduction, of at most 50% on the left-colon, by extending efficacy on the left-colon to the right-colon.
Virtual Colonoscopy (Computed Tomographic Colonography [CTC])
Virtual colonoscopy (also known as CTC or CT pneumocolon) refers to the examination of computer-generated images of the colon constructed from data obtained from an abdominal CT examination. These images simulate the effect of a conventional colonoscopy. Patients must take laxatives to clean the colon before the procedure, and the colon is insufflated with air (sometimes carbon dioxide) by insertion of a rectal tube just before radiographic examination.
A large, paired-design study was conducted by the American College of Radiology Imaging Network (ACRIN) group, with 2,531 average-risk people (prevalence of polyps or cancer ≥10 mm, 4%; mean age about 58 years) screened with both CTC and optical colonoscopy (OC). The gold standard was the OC, including repeat OC exams for people with lesions found by CTC but not by OC. Of 109 people with at least one adenoma or cancer 10 mm or larger, 98 (90%) were detected by CTC (referring everyone with a CTC lesion of ≥5 mm). Specificity was 86%, and PPV was 23%. There are several concerns from this study, including the following:
Unknowns from the study include the following for either OC or CTC:
Another study reported similar sensitivity and specificity in persons with an increased risk of CRC. In this study, the sensitivity of OC could not be determined because it was done in an unblinded manner. This study suggests that virtual colonoscopy might be an acceptable screening or surveillance test for persons with a high risk of CRC, but this cross-sectional study does not address outcome or frequency of testing in high-risk persons.
Some studies have assessed how well virtual colonoscopy can detect colorectal polyps without a laxative prep. The question is of great importance for implementation because the laxative prep required by both conventional colonoscopy and virtual colonoscopy is considered a great disadvantage by patients. By tagging feces with iodinated contrast material ingested during several days before the procedure, investigators in one study were able to detect lesions larger than 8 mm with 95% sensitivity and 92% specificity. The particular tagging material used in this study caused about 10% of patients to become nauseated; however, other materials are being assessed.
Another study  utilized low-fiber diet, orally ingested contrast, and "electronic cleansing," a process that subtracts tagged feces. CTC identified 91% of persons with adenomas 10 mm or larger, but detected fewer (70%) lesions of at least 8 mm. Patients who received both CTC and OC preferred CTC to OC (290 vs. 175). This study shows that CTC without a laxative prep detects small 1 cm lesions with high sensitivity and is acceptable to patients. Long-term utilization of CTC will depend on several issues including the frequency of follow-up exams that would be needed to detect smaller lesions that were undetected and may grow over time.
Extracolonic abnormalities are common in CTC. Fifteen percent of patients in an Australian series of 100 patients, referred for colonography because of symptoms or family history, were found to have extracolonic findings, and 11% of the patients needed further medical workups for renal, splenic, uterine, liver, and gallbladder abnormalities. In another study, 59% of 111 symptomatic patients referred for clinical colonoscopy in a Swedish hospital between June 1998 and September 1999 were found to have moderate or major extracolonic conditions on CTC. CTC was performed immediately before a colonoscopy and these findings required further evaluation. The extent to which follow-up of these incidental findings benefited patients is unknown.
Sixty-nine percent of 681 asymptomatic patients in Minnesota had extracolonic findings, of which 10% were considered to be highly important by the investigators, and required further medical workup. Suspected abnormalities involved kidney (34), chest (22), liver (8), ovary (6), renal or splenic arteries (4), retroperitoneum (3), and pancreas (1); however, the extent to which these findings will contribute to benefits or harms is uncertain. Two other studies, one large (n = 2,195) and one small (n = 136) examined the moderate or high importance of extracolonic findings from CTC. The larger study  found that 8.6% of patients had an extracolonic finding of at least moderate importance, while 24% of patients in the smaller study  required some evaluation for an extracolonic finding. The larger study found nine cancers from these evaluations, at a partial cost (they did not include all costs) of $98.56 per patient initially screened. The smaller study found no important lesions from evaluation, at a cost of $248 per person screened. Both of these estimates of cost are higher than previous studies have found. The extent to which any patients benefited from the detection of extracolonic findings is not clear. Because both of these studies were conducted in academic medical centers, the generalizability to other settings is also not clear. Neither of these studies examined the effect of extracolonic findings on patient anxiety and psychological function.
Technical improvements involving both the interpretation methodology, such as three dimensional (3-D) imaging, and bowel preparation are under study in many centers. While specificity for detection of polyps is homogeneously high in many studies, sensitivity can vary widely. These variations are attributable to a number of factors including characteristics of the CT scanner and detector, width of collimation, mode of imaging (two dimensional [2-D] vs. 3-D and/or "fly-through"), and variability in the expertise of radiologists.
Digital Rectal Examination
A case-control study reported that routine digital rectal examination was not associated with any statistically significant reduction in mortality from distal rectal cancer.
Detection of DNA Mutations in the Stool
The molecular genetic changes that are associated with the development of colorectal adenomas and carcinoma have been well characterized. Advanced techniques have been developed to detect several of these gene mutations that have been shed into the stool.[75,76,77,78] Stool DNA testing was recently assessed in a prospective study of asymptomatic persons who received colonoscopy, three-card FOBT (Hemoccult II), and stool DNA testing based on a panel of markers assessing 21 mutations. Conducted in a blinded way with prestated hypotheses and analyses, the study found that among 4,404 patients, the DNA panel had a sensitivity for CRC of 51.6% (for all stages of CRC) versus 12.9% for Hemoccult II, while the false-positive rates were 5.6% and 4.8%, respectively.[79,80]
A next-generation multitargeted stool test combined methylation markers for NDRG4 and BMP3, several KRAS mutations, and a human hemoglobin immunoassay. The markers, each quantitated separately, were combined using an algorithm in a prespecified multivariable analysis. The assay's sensitivity and specificity were compared with a commercial FIT test (OC FIT-CHEK Polymedco), using colonoscopy as the gold standard. Among 12,776 participants who had colonoscopy screening, were enrolled from 2011 through 2012 at 90 sites in the United States and Canada, and were aged 50 to 84 years (and weighted toward >65 years), 9,989 had fully evaluable results. There were 65 CRC and 757 advanced adenomas or sessile serrated polyps 1 cm or greater. The sensitivity for CRC was 92.3% (60 of 65 CRC) for the multitargeted test and 73.8% for FIT. Sensitivity for advanced lesions was 42.4% for the multitargeted test and 23.8% for FIT. Sensitivity for high-grade dysplasia was 69.2% for the multitarget test and 46.2% for FIT. Sensitivity for serrated sessile polyps 1 cm or greater was 42.4% for the multitargeted test and 5.1% for FIT. Specificities were 86.6% for the multitargeted test and 94.9% for FIT, using nonadvanced or negative colonoscopy results, and were 89.8% and 96.4% for totally negative colonoscopy results. A receiver operating characteristic (ROC) analysis showed that the multitargeted test has higher sensitivity than FIT alone, even if the FIT "cut-off" is reduced to try to increase sensitivity. A limitation is that there were no data about performance of repeated testing over time and what may be an appropriate testing interval.
Overall, the multitargeted test was more sensitive than FIT for both CRC and advanced precancerous lesions, but the test was less specific. The U.S. Food and Drug Administration approved this multitargeted test for colorectal screening in 2014.
Adherence to Screening
Benefit from CRC screening can only occur if eligible people are actually screened. There have been problems with screening adherence, particularly for low income and uninsured people. There has also been concern that some people may adhere less to screening with a colonoscopy than with fecal tests. One well-conducted RCT found that, among an uninsured population, mailed FIT-kit outreach and follow-up reminder phone calls resulted in an adherence rate of 40.7%. Mailed colonoscopy invitations and follow-up phone reminders resulted in a 24.6% adherence rate. The usual-care adherence rate in this trial was 12.1%.
Tailoring Screening to Risk
Benefit of screening might be improved by tailoring the recommended screening test to a person's degree of CRC risk. For example, if a subgroup of young women were to have a substantially lower risk of proximal neoplasms, then recommending sigmoidoscopy instead of colonoscopy (both are recommended by the U.S. Preventive Services Task Force without preference, as part of a program of screening persons with average risk) might lead to higher compliance.
In a study to identify persons in an average-risk group who had a higher versus lower risk of advanced neoplasia (CRC and advanced adenomas) anywhere in the colon, 2,993 persons having a screening colonoscopy were stratified by age, gender, waist circumference, smoking, and family history (persons in high-risk family categories, e.g., Lynch syndrome or adenomatous polyposis coli, were excluded). In a classification system derived in a training set, the risks of advanced neoplasm in four groups were: 1.92%, 4.88%, 9.93%, and 24%. In the two lowest risk groups, sigmoidoscopy would have detected 51 (73%) of 70 advanced neoplasms. In the independent validation set, results were similar. Whether this system increases overall compliance has yet to be determined.
A similar stratification system based on age, gender, smoking, and family history-and combined with FIT-was tested in Asia to determine whether use of the stratification system plus FIT could detect which persons need colonoscopy. If either the stratification system or FIT was positive, a person was recommended for colonoscopy. Using this strategy, 95% of persons with CRC were correctly told to have colonoscopy.
Potential harms are associated with the modalities used to screen for colorectal cancer (CRC), some of which have sufficient evidence and some that do not.
The tables for each screening test below show the magnitude of burden for several categories of harms encountered along the screening cascade. The magnitude of harms is a combination of the frequency and severity of harm, as perceived by the patient.
Harms are defined broadly as any negative effect on individuals or populations resulting from being involved in the screening process (cascade) compared with not screening. Potential harms are organized according to the type of harm (e.g., physical, psychological and hassle/opportunity costs) and when they occur in the screening cascade (e.g., screening test/workup; screening test/workup results; surveillance and surveillance results; and early treatment and overtreatment). For example, potential harms of screening colonoscopy include harms of the screening test itself (e.g., perforation and bleeding), results of the screening test (e.g., anxiety from an abnormal result), surveillance (e.g. harms of more frequent colonoscopies), and treatment (e.g. earlier treatment or overtreatment). For other colorectal cancer screening tests, there are also harms associated with the workup (e.g. colonoscopy for positive fecal occult blood test [FOBT]). For all aspects of participating in the screening cascade, there are time/effort and opportunity costs (nonfinancial harms) for the patient. We do not include here any financial harms to the patient/family, nor any psychological harm from anticipation of future financial costs related to screening.
The potential physical harms of colonoscopy include adverse effects from the preparation and adverse effects from the procedure (colonic perforation and bleeding; effects of sedation).[3,4,5] These complications can be serious, requiring hospitalization. Colonic perforation and serious bleeding occur more often with biopsy or polypectomy, with an overall average of three to five serious complications per 1,000 procedures. The physical harm of discomfort during the procedure has been reduced by sedation, although sedation has its own potential for physical harm (magnitude and severity uncertain due to insufficient evidence).
Physical harms are also associated with further steps in the screening cascade, including diagnosis of CRC (some large ecologic studies have shown an increase in suicide soon after diagnosis) and overdiagnosis/overtreatment due to treating lesions that would never have caused the patient important problems (evidence insufficient to determine magnitude and severity).
The potential psychological harms of colonoscopy include anticipation of the procedure and anxiety while awaiting the results of biopsy reports. For people with polyps, there may be increased distress in considering oneself at increased risk of CRC (evidence insufficient). For people newly diagnosed with CRC, many will experience increased anxiety and depression for at least 6 months, as prognosis and treatment are discussed (evidence insufficient).
The harm of time/effort and opportunity costs involved in moving through the demands of the screening cascade are present throughout the process (evidence insufficient to determine frequency and severity).
FOBT/immunochemical FOBT (FIT)
The potential physical harms of fecal-based testing include the same harms as for colonoscopy for people with a positive test who have been referred for diagnostic colonoscopy.
The potential psychological harms, as well as time/effort and opportunity costs are also similar to the description above for colonoscopy (refer to the Colonoscopy section in the Evidence of Harms section of this summary for more information). These harms are associated with moving through the screening cascade, regardless of the initial screening test. Although it is highly likely that these psychological harms, plus time/effort and opportunity costs, do occur, the exact frequency and severity of these harms are uncertain due to insufficient evidence.
The potential physical harms of sigmoidoscopy are considerably less than those of colonoscopy, with a less intensive preparation. Serious procedural complications occur in perhaps three in 10,000 sigmoidoscopies compared with in three in 1,000 colonoscopies. There is usually no sedation with sigmoidoscopy, thus again lowering the potential for complications.
The potential psychological harms of sigmoidoscopy screening, as well as the time/effort and opportunity costs of screening, are the same as given above for other screening strategies.
Computed tomography colonography (CTC)
The potential physical harms due directly to the procedure of CTC are less than either colonoscopy or sigmoidoscopy, with rare procedural complications. However, CTC does involve repeated radiation exposure, with uncertain associated harms, and it also detects a number of extra-colonic incidental findings.[7,8,9,10,11] Incidental findings have been detected in between 40% to 98% of CTCs, with a variable number of these considered significant enough to proceed with further diagnostic testing. As there is little evidence that early detection of any of these findings could improve health outcomes for patients, these findings may be considered as harms until proven otherwise.
The potential psychological harms or time/effort and opportunity costs for CTC are similar to the descriptions above for patients moving through the screening cascade (evidence insufficient to determine frequency and severity).
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Description of the Evidence
Revised Table 4 to include the percentage of individuals in the screened group who received a flexible sigmoidoscopy and a follow-up colonoscopy when the sigmoidoscopy was positive. Also added the percentage of colorectal cancer incidence.
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about colorectal cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."
The preferred citation for this PDQ summary is:
PDQ® Screening and Prevention Editorial Board. PDQ Colorectal Cancer Screening. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/colorectal/hp/colorectal-screening-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389266]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website's Email Us.
Last Revised: 2017-03-29
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
Addiction is treated by our Behavioral Health Doctors.
4 Medical Blvd,
Hattiesburg, MS 39402
27 B South 6th Street
Bay Springs, MS 39422
Covington County Hospital
701 S. Holly Ave
Collins, MS 39428
CONNECT WITH FORREST HEALTH
Notice of Privacy Practices · PUBLIC RECORDS REQUEST · FINANCIAL ASSISTANCE · NON-DISCRIMINATION NOTICE
REQUEST FROM LAW ENFORCEMENT FOR RELEASE OF PROTECTED HEALTH INFORMATION 6051 US HIGHWAY 49, HATTIESBURG MS 39401 · 601-288-7000 · © FORREST HEALTH · ALL RIGHTS RESERVED ·